Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells.

about

Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells.

Item

http://www.wikidata.org/entity/Q38731503

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Hetrombopag, a Thrombopoietin ...... as an Enhancer of Stem Cells.

@en

type

Item

label

Hetrombopag, a Thrombopoietin ...... as an Enhancer of Stem Cells.

@en

prefLabel

Hetrombopag, a Thrombopoietin ...... as an Enhancer of Stem Cells.

@en

P1476

Hetrombopag, a Thrombopoietin ...... as an Enhancer of Stem Cells.

@en

P2093

Chengwei Zou

http://www.w3.org/2001/XMLSchema#string

Jianchun Wang

http://www.w3.org/2001/XMLSchema#string

Nannan Zhou

http://www.w3.org/2001/XMLSchema#string

Xiaodong Li

http://www.w3.org/2001/XMLSchema#string

Yong Zhao

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Monitoring of bone marrow cell homing into the infarcted human myocardium.

Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.

Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy.

Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.

Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

P304

567-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10557-016-6696-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27838864

http://www.w3.org/2001/XMLSchema#string